AgingResearch.NewsJoin free

Akcea Therapeutics

CompanyUnited States

Akcea Therapeutics develops one asset, in phase 3 (Pelacarsen in acute coronary syndrome). Mostly oligonucleotide acting on lipid and ceramide metabolism and LPA; based in the United States.

1
Asset
Furthest stage
Phase 3
2
Trials
0
Signals

Pipeline

1

  • Pelacarsen

    Antisense oligonucleotide reduces hepatic apolipoprotein(a) synthesis, lowering circulating lipoprotein(a).

    Phase 3, Oligonucleotide, Lipid and ceramide metabolism, LPA, acute coronary syndrome, atherosclerotic cardiovascular disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials2
  • Signals2
  • Similar companies6

Intelligence